IP Library Granted Patent US 10,598,955
Granted Patent B2
US 10,598,955 · App. 15/165,044 · Granted Mar 24, 2020

Method for obtaining contact lenses with dynamically controlled sagitta and clearance

Inventor: Charles H. Creighton (West Seneca, NY)
Assignee: Bausch & Lomb Incorporated
G02C7/028B29D11/00086G02C7/024G02C7/027G02C7/04G02C7/047B29K2033/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,598,955
App. No.
15/165,044
Granted
Mar 24, 2020
Kind
B2
Abstract

The disclosure generally describes methods, systems and products relating to the development and manufacture of scleral contact lenses. A number of dimensions for the scleral lens is generated based on control points and attendant curvature parameters. Any change to one or more of the curve parameters imparts an improved anterior and posterior surface of the scleral lens and associated thickness, while undesired modifications to control points and other curve parameters remain static inasmuch as the sagittal depth component is an input parameter of the present disclosure.

Claims (78)

1. A method of manufacturing a scleral contact lens, comprising:

(a) providing a predicate scleral contact lens having a surface comprising a base curve segment positioned in a central portion of the lens, a dynamic curve segment peripherally surrounding the base curve segment, a limbal clearance curve segment peripherally surrounding the dynamic curve segment, and a peripheral curve segment peripherally surrounding the limbal clearance curve segment, wherein the base curve segment is defined by segment parameter components comprising a base curve sagittal component SA, a base curve radius component RA, and a base curve chord diameter component DA, the dynamic curve segment is defined by segment parameter components comprising a dynamic curve sagittal component SB, a dynamic curve radius component RB, and a dynamic curve chord diameter component DB, the limbal clearance curve segment is defined by segment parameter components comprising a limbal clearance curve sagittal component SC, a limbal clearance curve radius component RC, and a limbal clearance curve chord diameter component DC, the peripheral curve segment is defined by segment parameter components comprising a peripheral curve sagittal component SD, a peripheral curve radius component RD, and a peripheral curve chord diameter component DD, and the lens has a total sagittal clearance ST;

(b) selecting one or more control points selected from a central vault clearance, a mid-peripheral clearance, and a limbal clearance of the predicate contact lens that are to be adjusted, and one or more of such control points that are not to be adjusted, for forming the scleral contact lens to be manufactured relative to the predicate lens;

(c) altering one or more segment parameters of the predicate lens selected from the group consisting of the base curve segment, the dynamic curve segment, and the limbal clearance curve segment for adjusting each of the control points to be adjusted, in accordance with a computer implemented algorithm on computer readable media, wherein a change in one or more of the components for each of the one or more segment parameters is associated with a corresponding change in the one or more control points to be adjusted, and further wherein changes to any single segment parameter modify the contact lens at a control point to be adjusted of the one or more control points and do not modify the contact lens at control points not to be adjusted of the one or more control points, wherein (i) a change in the central vault clearance control point corresponds to changes to the dynamic curve sagittal component and to the total sagittal clearance of the lens, (ii) a change in the mid-peripheral clearance control point corresponds to changes to the dynamic curve sagittal component and to the base curve sagittal component, and (iii) a change in the limbal clearance control point corresponds to changes to the dynamic curve sagittal component and the limbal sagittal component, and wherein each of the base curve radius component, the dynamic curve radius component, and the limbal clearance curve radius component represent radii of curvature for arcs with respect to a central optical axis of the contact lens, and at least one of (iv)-(vi) is performed:

(iv) an adjustment to the total sagittal clearance of the predicate lens is specified and changes to the dynamic curve sagittal component and dynamic curve radius component of the predicate lens are calculated to effect changes in the central vault clearance control point of the lens to be manufactured, in accordance with the algorithms

ST 1=Specified

SB 1= ST 1− SA−SC

and

RB 1=SQRT((( DA/ 2){circumflex over ( )}2)+(((((( DB/ 2){circumflex over ( )}2)-(( DA/ 2){circumflex over ( )}2)+( SB 1{circumflex over ( )}2))/(2* SB 1)){circumflex over ( )}2))),

wherein ST1 is the specified adjusted total sagittal clearance, SB1 is the calculated changed dynamic curve sagittal component, and RB1 is the calculated changed dynamic curve radius component,

(v) an adjustment to the base curve radius of the predicate lens is specified and changes to the dynamic curve sagittal component, the dynamic curve radius component and the base curve sagittal component of the predicate lens are calculated to effect changes in the mid-peripheral clearance control point of the lens to be manufactured, in accordance with the algorithms

RA 2=Specified

SA 2= RA 2−sqrt( RA 2{circumflex over ( )}2−( DA/ 2){circumflex over ( )}2)

SB 2= ST−SA 2− SC

and

RB 2=SQRT((( DA/ 2){circumflex over ( )}2)+(((((( DB/ 2){circumflex over ( )}2)−(( DA/ 2){circumflex over ( )}2)+( SB 2{circumflex over ( )}2))/(2* SB 2)){circumflex over ( )}2))),

wherein RA2 is the specified adjusted base curve radius, SA2 is the calculated changed base curve sagittal component, SB2 is the calculated changed dynamic curve sagittal component, and RB2 is the calculated changed dynamic curve radius component, and

(vi) an adjustment to the limbal clearance curve radius of the predicate lens is specified and changes to the dynamic curve sagittal component, the dynamic curve radius component and the limbal clearance curve sagittal component of the predicate lens are calculated to effect changes in the limbal clearance control point of the lens to be manufactured, in accordance with the algorithms

RC 3=Specified

SC 3= RC 3−sqrt( RC 3{circumflex over ( )}2−( DC/ 2){circumflex over ( )}2− RC 3−sqrt( RC 3{circumflex over ( )}2−( DB/ 2){circumflex over ( )}2)

SB 3= ST−SA−SC 3

and

RB 3=SQRT((( DA/ 2){circumflex over ( )}2)+(((((( DB/ 2){circumflex over ( )}2)−(( DA/ 2){circumflex over ( )}2)+( SB 3{circumflex over ( )}2))/(2* SB 3)){circumflex over ( )}2))),

wherein RC3 is the specified adjusted limbal clearance curve radius, SC3 is the calculated changed limbal clearance curve sagittal component, SB3 is the calculated changed dynamic curve sagittal component, and RB3 is the calculated changed dynamic curve radius component; and

(d) forming a scleral contact lens to have a surface corresponding to the altered segment parameters.

2. The method of claim 1 , further comprising adjusting a scleral alignment angle of the lens to be manufactured relative to the predicate lens by adjusting one or more component of the peripheral curve segment of the predicate lens.

3. The method of claim 1 , wherein the sagittal component of the base curve, the dynamic curve and the limbal clearance curve comprise the total sagittal clearance for the contact lens.

4. The method of claim 2 , wherein changes to the sagittal component of the peripheral curve do not impact the total sagittal clearance.

5. The method of claim 1 , wherein an adjustment to the total sagittal clearance of the predicate lens is specified and changes to the dynamic curve sagittal component and dynamic curve radius component of the predicate lens are calculated to effect changes in the central vault clearance control point of the lens to be manufactured, in accordance with the algorithms

ST 1=Specified

SB 1= ST 1− SA−SC

and

RB 1=SQRT((( DA/ 2){circumflex over ( )}2)+(((((( DB/ 2){circumflex over ( )}2)−(( DA/ 2){circumflex over ( )}2)+( SB 1{circumflex over ( )}2))/(2* SB 1)){circumflex over ( )}2))),

wherein ST1 is the specified adjusted total sagittal clearance, SB1 is the calculated changed dynamic curve sagittal component, and RB1 is the calculated changed dynamic curve radius component.

6. The method of claim 1 , wherein an adjustment to the base curve radius is specified and changes to the dynamic curve sagittal component, the dynamic curve radius component and the base curve sagittal component of the predicate lens are calculated to effect changes in the mid-peripheral clearance control point of the lens to be manufactured, in accordance with the algorithms

RA 2=Specified

SA 2= RA 2−sqrt( RA 2{circumflex over ( )}2−( DA/ 2){circumflex over ( )}2)

SB 2= ST−SA 2− SC

and

RB 2=SQRT((( DA/ 2){circumflex over ( )}2)+(((((( DB/ 2){circumflex over ( )}2)−(( DA/ 2){circumflex over ( )}2)+( SB 2{circumflex over ( )}2))/(2* SB 2)){circumflex over ( )}2))),

wherein RA2 is the specified adjusted base curve radius, SA2 is the calculated changed base curve sagittal component, SB2 is the calculated changed dynamic curve sagittal component, and RB2 is the calculated changed dynamic curve radius component.

7. The method of claim 1 , wherein an adjustment to the limbal clearance curve radius is specified and changes to the dynamic curve sagittal component, the dynamic curve radius component and the limbal clearance curve sagittal component of the predicate lens are calculated to effect changes in the limbal clearance control point of the lens to be manufactured, in accordance with the algorithms

RC 3=Specified

SC 3= RC 3−sqrt( RC 3{circumflex over ( )}2−( DC/ 2){circumflex over ( )}2− RC 3−sqrt( RC 3{circumflex over ( )}2−( DB/ 2){circumflex over ( )}2)

SB 3= ST−SA−SC 3

and

RB 3=SQRT((( DA/ 2){circumflex over ( )}2)+(((((( DB/ 2){circumflex over ( )}2)−(( DA/ 2){circumflex over ( )}2)+( SB 3{circumflex over ( )}2))/(2* SB 3)){circumflex over ( )}2))),

wherein RC3 is the specified adjusted limbal clearance curve radius, SC3 is the calculated changed limbal clearance curve sagittal component, SB3 is the calculated changed dynamic curve sagittal component, and RB3 is the calculated changed dynamic curve radius component.

8. The method of claim 1 , wherein the base curve, dynamic curve, limbal clearance curve and peripheral curve are the segment parameters for a spherical curve.

9. The method of claim 1 , wherein the base curve, dynamic curve, limbal clearance curve and peripheral curve are the segment parameters for an aspheric curve.

10. The method of claim 9 , wherein the aspheric curve is selected from the group consisting of conical sections, polynomials, splines, straight lines, angled lines, tapered lines, polygonal curves, rectangular, square, circular, diagonal, concentric, patterned, perimetric, hexagonal, or triangular configurations, or any free form line possessing a start point, an end point, and connects two defined points in space, and/or other shapes that are congruent for use as a sagittal component.

11. The method of claim 1 , further comprising defining one or more additional segment parameter curves and/or one or more additional control points selected from the group consisting of one or more curves and/or sagittal components, wherein all the curves and/or sagittal components are defined for the contact lens other than the dynamic curve sagittal component, and wherein the dynamic curve sagittal component is calculated to achieve a desired total sagittal clearance.

12. The method of claim 1 , wherein each of the sagittal components is calculated in accordance with an algorithm defined by:

Notation

Parameter

Formula/Calculation

(SA)

Base Curve

= RA − sqrt(RA{circumflex over ( )}2 − (DA/2){circumflex over ( )}2)

(SC)

Limbal

= RC − sqrt(RC{circumflex over ( )}2 − (DC/2){circumflex over ( )}2) −

Clearance Curve

RC − sqrt(RC{circumflex over ( )}2 − (DB/2){circumflex over ( )}2)

(SD)

Peripheral Curve

= RD − sqrt(RD{circumflex over ( )}2 − DD/2){circumflex over ( )}2) −

RD − sqrt(RC{circumflex over ( )}2 − (DC/2){circumflex over ( )}2)

(SB)

Dynamic Curve

= Stotal − SD − SC − SA

Sagittal

Component

(RB)

Dynamic Curve

= SQRT(((DA/2){circumflex over ( )}2) + ((((((DB/2){circumflex over ( )}2) −

Radius

((DA/2){circumflex over ( )}2)) + (SB{circumflex over ( )}2))/(2*SB)){circumflex over ( )}2)).

Assignments (23)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072469/0091 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
PATENT SECURITY AGREEMENT Recorded Oct 4, 2023
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 065120/0086 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 056811/0814) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061872/0669 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 059121/0001) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061873/0001 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 043045/0891) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061874/0361 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 048556/0758) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH COMPANIES INC.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0484 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 042584/0861) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061775/0655 →
PATENT SECURITY AGREEMENT Recorded May 10, 2022
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A. AS COLLATERAL AGENT
Reel/Frame 059913/0548 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: ALDEN OPTICAL LABORATORIES, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043045/0891 →
SECURITY AGREEMENT Recorded May 25, 2017
From: ALDEN OPTICAL LABORATORIES, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SPROUT PHARMACEUTICALS, INC.; SYNERGETICS USA, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 042584/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2017
From: CREIGHTON, CHARLES H.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 042205/0279 →
Continuity (3)
Provisional Application 62180004 · Jun 15, 2015
Provisional Application 62168148 · May 29, 2015
Related Publication 20160349535A1 · Dec 1, 2016
Cited By (1)
US 12,386,200